Importance of off-label options for treating serious lung diseases

Annals of the American Thoracic Society

Volumn 13, Issue 11, 2016, Pages 1879-1880

  O'Sullivan, Brian P ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENEFICENCE; CLINICAL TRIAL (TOPIC); CYSTIC FIBROSIS; DRUG APPROVAL; DRUG EFFICACY; ECONOMIC ASPECT; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HEALTH CARE ACCESS; HUMAN; INFORMED CONSENT; JUSTICE; LUNG DISEASE; MEDICAL DECISION MAKING; MEDICAL ETHICS; MORALITY; OFF LABEL DRUG USE; PATIENT AUTONOMY; PHYSICIAN; REIMBURSEMENT;

HUMANS; LUNG DISEASES; OFF-LABEL USE;

EID: 84995450768     PISSN: 23256621     EISSN: None     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201608-640ED     Document Type: Editorial

References (13)

1. VanDevanter DR, Heltshe SL, LiPuma JL. Potential for therapeutic benefit among cystic fibrosis populations excluded from clinical trials or labeling of marketed therapies. Ann Am Thorac Soc 2016;13: 1890-1893.
2. Brody H, Light DW. The inverse benefit law: how drug marketing undermines patient safety and public health. Am J Public Health 2011;101:399-404.
3. Brill S. America's most admired lawbreaker. New York: The Huffington Post [accessed 2016 Aug 26]. Available from: http://highline. huffingtonpost.com/miracleindustry/americas-most-admiredlawbreaker/
4. Liang BA, Mackey T. Health care policy. Reforming off-label promotion to enhance orphan disease treatment. Science 2010;327:273-274.
5. Walker J. Costly Vertex drug is denied, and Medicaid patients sue. Wall Street Journal; July 16, 2014 [accessed 2016 Aug 26]. Available from: http://www.wsj.com/articles/costly-drug-vertex-is-denied-andmedicaid- patients-sue-1405564205
6. Teceshi B. Are insurance policies saving patients money, or keeping them from the treatment they need? STAT [accessed 2016 Aug 26]. Available from: https://www.statenews.com/2016/08/22/steptherapy- patients-insurance-treatments/
7. Courtright K. POINT: Do randomized controlled trials ignore needed patient populations? Yes. Chest 2016;149:1128-1130.
8. Frattarelli DA, Galinkin JL, Green TP, Johnson TD, Neville KA, Paul IM, Van Den Anker JN; American Academy of Pediatrics Committee on Drugs. Off-label use of drugs in children. Pediatrics 2014;133: 563-567.
9. Stafford RS. Regulating off-label drug use: rethinking the role of the FDA. N Engl J Med 2008;358:1427-1429.
10. Roehr B. Abbott pays $1.6bn for promoting off label use of valproic acid. BMJ 2012;344:e3343.
11. Ratner M. Pfizer settles largest ever fraud suit for off-label promotion. Nat Biotechnol 2009;27:961-962.
12. Wilkes M, Johns M. Informed consent and shared decision-making: a requirement to disclose to patients off-label prescriptions. PLoS Med 2008;5:e223.
13. Green AK, Wood WA, Basch EM. Time to reassess the cancer compendia for off-label drug coverage in oncology. JAMA [online ahead of print] 2016 Aug 25; DOI: 10.1001/jama.2016.12770.